

## DIASTOLIC FUNCTION IS IMPAIRED IN DOGS WITH MYXOMATOUS MITRAL VALVE DISEASE

### *DISFUNÇÃO DIASTÓLICA EM CÃES COM DOENÇA MIXOMATOSA DA VALVA MITRAL*

**R. R. CAMACHO<sup>1</sup>; M. G. SOUSA<sup>2</sup>; R. P. FRANCO<sup>3</sup>; F. N. GAVA<sup>4</sup>; A. A. CAMACHO<sup>5</sup>**

#### SUMMARY

Myxomatous mitral valve disease (MMVD) is the most common cardiac disease in dogs, and the echocardiogram is required to investigate the degree of remodeling and the intensity of cardiac dysfunction. Therefore, the aim of this study was to assess diastolic function in dogs with MMVD in different stages, and to compare them with healthy animals. This study enrolled 12 mature dogs with MMVD, which were subdivided in two groups: stage B2 (n=7) and stage C (n=5). Also, 9 healthy adult dogs were recruited to serve as controls. Several echocardiographic data were obtained for the assessment of diastolic function, as well as some parameters intended to evaluate the cardiac structure and systolic function, which were used to search for correlations with the diastolic parameters. Concerning diastolic function, a significant difference was found to exist between groups for the peak velocity of left ventricular slow filling, the isovolumic relaxation time, and the mitral annular velocities at early and late diastole. These findings are associated with the structural and hemodynamic changes ascribed to the progression of MMVD and the intensification of congestive heart failure. The indices calculated from the peak velocity of left ventricular rapid filling and the mitral annular velocities obtained at early and late diastole also differed between healthy and diseased dogs. Because some of these indices are surrogates for left ventricular filling pressure and the congestive status of the patient, the results of this study are supportive of the relationship between the progression of MMVD and diastolic impairment, besides the eccentric structural remodeling attributable to this cardiac disease.

**KEY-WORDS:** Cardiac disease. Valve disease. Animals. Echocardiography. Cardiac function.

#### RESUMO

A degeneração mixomatosa da valva mitral (DMVM) é a cardiopatia de maior prevalência em cães e a ecocardiografia é necessária para avaliar o grau de remodelamento e a intensidade da disfunção cardíaca. Assim, o escopo desta pesquisa foi avaliar a função diastólica em cães com DMVM em diferentes estágios, comparando-os com cães saudáveis. Foram arrolados 12 cães adultos portadores de DMVM, os quais foram subdivididos em dois grupos: estágio B2 (n=7) e estágio C (n=5). Além disso, foi constituído um grupo controle com 9 cães adultos clinicamente saudáveis. Foram obtidos parâmetros ecocardiográficos para avaliação da função diastólica, assim como algumas variáveis para avaliação estrutural do coração e da função sistólica, as quais foram empregadas para investigar correlações com os parâmetros diastólicos. No tocante à função diastólica, houve diferença significativa entre grupos na avaliação da velocidade máxima do enchimento ventricular esquerdo lento, do tempo de relaxamento isovolumétrico e das velocidades anulares da mitral em início e final da diástole. Tais resultados refletem modificações estruturais e hemodinâmicas que acompanham a progressão da enfermidade mitral e a intensificação da insuficiência cardíaca congestiva. Os índices calculados a partir das relações entre a velocidade máxima do enchimento ventricular esquerdo rápido e as velocidades anulares da mitral, bem como entre as velocidades anulares da mitral obtidas no início e final da diástole, também foram diferentes entre cães saudáveis e enfermos. Como alguns desses parâmetros refletem a pressão de enchimento do ventrículo esquerdo e o estado congestivo do paciente, os resultados desta pesquisa apontam para a relação existente entre a progressão da DMVM e o prejuízo diastólico, além do remodelamento estrutural excêntrico que acompanha essa enfermidade.

**PALAVRAS-CHAVE:** Cardiopatias. Endocardiose. Animais. Ecocardiografia. Função cardíaca.

<sup>1</sup> Doutorando do Programa de Pós-graduação em Medicina Veterinária, Unesp, Campus de Jaboticabal, SP, Brasil.

<sup>2</sup> Prof. Adjunto da Universidade Federal do Paraná, UFPR, Curitiba, PR, Brasil.

<sup>3</sup> Prof. Doutor de Medicina Veterinária da Universidade de Marília, UNIMAR, SP, Brasil.

<sup>4</sup> Pós-doutorado da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, SP, Brasil.

<sup>5</sup> Professor Titular da Universidade Estadual Paulista, UNESP, Campus de Jaboticabal, SP, Brasil.

## INTRODUCTION

Myxomatous mitral valve disease (MMVD) is the most common cardiac disease in dogs. Although the pathophysiology of MMVD is still not completely understood, a hereditary genetic basis was already demonstrated to be responsible for the valve degeneration in Cavalier King Charles Spaniel dogs (THRUSFIELD et al., 1985; HAGGSTROM et al., 1992; BEARDOW e BUCHANAN, 1993; WARE, 2007).

This degeneration is characterized by mitral valve structural disarray, which eventually progress up to impair the ability of the valve to avoid the backflow of blood from the left ventricle towards the left atrium during ventricular systole. Blood regurgitation results in left atrial dilation and is responsible for the development of clinical signs over time (MUCHA, 2001; ATKINS et al. 2007; BORGARELLI et al. 2008).

Reducing the stroke volume activates the renin-angiotensin-aldosterone system to increase preload, but the vasoconstrictive effect of angiotensin II also interferes with afterload. The upregulated activity of angiotensin II results in myocyte hypertrophy and remodeling of the extracellular matrix, which is characterized by the augmented synthesis of collagen III, interstitial fibrosis, myocyte atrophy and apoptosis. Also, because aldosterone is involved with fibroblasts [mRNA] transcription, causing its proliferation and the deposition of collagen within the heart tissue, it does play an important role in cardiac remodeling. All these alterations are responsible for the passive stiffness of the ventricles and arterial bed, therefore interfering with ventricular filling and arterial compliance (SERRO AZUL et al., 1977).

Diastolic function is related with the capacity of the heart to overwhelm the altered preload, therefore maintaining intracardiac pressures within the physiological range and a normal stroke volume. With this in mind, diastolic dysfunction is likely to represent a key surrogate for congestive heart failure. In dogs, it is well known that the progression of MMVD is associated with myocardial remodeling and the deterioration of contractile function (BONAGURA & SCHOBERT, 2009). However, little is known concerning the impairment of relaxation and compliance in these patients in accordance with the intensification of congestion. In this study, the authors hypothesized that congestion plays a major role in diastolic dysfunction. Therefore, the aim of this study was twofold: to investigate diastolic function in dogs with MMVD and varying degrees of congestive heart failure, and to assess the relation between diastolic parameters, systolic data, and cardiac remodeling assessed by echocardiography.

## MATERIAL E METHODS

Dogs with MMVD and remodeled hearts, either asymptomatic or presenting overt clinical signs attributable to CHF, were enrolled into a prospective cross-sectional observational study. The diagnosis of MMVD was based on physical examination and ancillary techniques, including a complete transthoracic

echocardiogram. Altered laboratory analysis, including CBC and biochemistry, were considered exclusion criteria, as were the absence of cardiac remodeling and other pulmonary diseases documented on chest radiographs. Once included in the study, MMVD dogs were categorized in groups in accordance with the ACVIM consensus statement on canine valvular disease (ATKINS et al, 2009). Also, normal age-matched dogs were recruited from the university experimental kennel to serve as healthy controls.

The echocardiogram was performed with the dogs restrained in right and left lateral recumbencies, using a 5.0-7.5 MHz transducer. Images were acquired and stored for offline measurements, which included parameter of diastolic function, systolic function, and cardiac morphology. Diastolic data included the peak velocity of left ventricular rapid filling (mitral E wave:  $E_m$ ), the peak velocity of left ventricular slow filling (mitral A wave:  $A_m$ ), and the isovolumic relaxation time (IVRT), which were obtained using pulsed-wave Doppler. These parameters required either an apical 4- or 5-chamber image obtained from the left parasternal window. Also, tissue Doppler imaging was used to acquire mitral annular velocity at early and late diastole, which was obtained at both the septal and lateral and averaged to produce the mean annular velocities ( $E_{TDI}$ ,  $A_{TDI}$ ) sites. Several indices were calculated from these parameters, including the  $E_m$ -to- $A_m$  ratio ( $E_m/A_m$ ),  $E_{TDI}$ -to- $A_{TDI}$  ratio ( $E_{TDI}/A_{TDI}$ ),  $E_m$ -to- $E_{TDI}$  ratio ( $E_m/E_{TDI}$ ), and  $A_m$ -to- $A_{TDI}$  ratio ( $A_m/A_{TDI}$ ). The echocardiographic parameters aimed at assessing systolic function and cardiac morphology included the left ventricular end-diastolic ( $LV_d$ ) and end-systolic ( $LV_s$ ) diameters, left atrium-to-aorta ratio ( $LA/Ao$ ), fractional shortening (FS), ejection fraction (EF), and the mitral annular systolic velocity at both the septal and lateral sites, whose average value was considered as the mean annular systolic velocity ( $S_{TDI}$ ). All echocardiographic information represented the mean of at least three consecutive cardiac cycles, and were obtained in accordance with the guidelines described elsewhere (BOON, 2011).

All data underwent the Shapiro-Wilk normality test. Whenever a normal distribution was attained, an analysis of variance followed by the post-hoc Tukey test was used to compare MMVD groups with the controls. When data was not normally distributed, we used Kruskal-Wallis test followed by Dunn's multiple comparisons test instead. Also, significant correlations between diastolic parameters and the echocardiographic surrogates of systolic function and cardiac remodeling were investigated using either the Pearson or Spearman correlation coefficients. All analyses were performed with the software Graphpad Prism® v.3.00, and significance was set at  $P < 0.05$ .

## RESULTS

Twelve adult dogs (3.0-17.3 kg) with MMVD and dilated hearts were included into this investigation. Cardiac remodeling was determined based on the increased  $LA/Ao$  ratio ( $>1.4$ ) and VHS ( $>10.5$ ). Seven

mature animals (10.2-14.0 kg) had no clinical signs at all, and were included in stage B2 group, while five adult dogs (3.0-14.0 kg) already exhibited clinical signs ascribed to heart failure and were categorized into stage C. Finally, nine mature dogs (10.2-17.3 kg) that presented no murmur on auscultation nor exhibited any clinical signs were recruited to serve as healthy controls. Body weight was not considered statistically different ( $P=0.4049$ ) between groups.

While the peak velocity of left ventricular slow filling ( $A_m$ ) and the mean late diastolic annular velocity ( $A_{TDI}$ ) increased significantly with the progression of MMVD, a reduction was observed for IVRT and the early diastolic annular velocity (Table 1). Although  $E_m$  and  $E_{TDI}$  remained unchanged between groups, the variation documented for  $A_m$  and  $A_{TDI}$  resulted in significant differences for  $E_m/A_m$  and  $E_{TDI}/A_{TDI}$  between healthy and MMVD dogs (Table 2). Changes in cardiac morphology ascribed to the progression of MMVD were

demonstrated by the increase in LA/Ao ratio and the left ventricular end-diastolic diameter ( $LV_d$ ). However, cardiac systolic function was apparently preserved as the comparison of systolic surrogates in MMVD dogs were similar to those recorded in healthy subjects (Table 3).

Significant correlations were documented between LA/Ao and  $A_m$  ( $R=0.5714$ ;  $P=0.0068$ ), IVRT ( $R=-0.4810$ ;  $P=0.0273$ ),  $A_{TDI}$  ( $R=0.5992$ ;  $P=0.0273$ ),  $E_m/A_m$  ( $R=-0.4698$ ;  $P=0.0316$ ),  $E_{TDI}/A_{TDI}$  ( $R=-0.5700$ ;  $P=0.0070$ ),  $E_m/E_{TDI}$  ( $R=0.4704$ ;  $P=0.0314$ ); between  $LV_{d-index}$  and  $E_m/E_{TDI}$  ( $R=-0.4614$ ;  $P=0.0205$ ); between FS and  $A_{TDI}$  ( $R=0.5106$ ;  $P=0.0180$ ),  $E_{TDI}/A_{TDI}$  ( $R=-0.5359$ ;  $P=0.0123$ ),  $A_m/A_{TDI}$  ( $R=-0.4999$ ;  $P=0.0210$ ); between EF and  $A_{TDI}$  ( $R=0.5010$ ;  $P=0.0207$ ),  $E_{TDI}/A_{TDI}$  ( $R=-0.5488$ ;  $P=0.0100$ ),  $A_m/A_{TDI}$  ( $R=-0.5995$ ;  $P=0.0070$ ); and finally, between  $S_{TDI}$  and  $E_m/E_{TDI}$  ( $R=0.4354$ ;  $P=0.0485$ ) (Figures 1 and 2).

**Table 1** - Means (SD) or medians (IQR) of the diastolic parameters obtained by transthoracic echocardiography from healthy (n=9) and MMVD dogs (n=12).

	Groups			P
	Healthy	Stage B2	Stage C	
$E_m$ (cm/s) *	80.5 (63.5-84.3)	80.7 (77.4-86.9)	72.7 (63.0-110.7)	0.2887
$A_m$ (cm/s)	49.8 (14.2) <sup>A</sup>	79.8 (20.2) <sup>B</sup>	66.7 (22.5) <sup>AB</sup>	0.0172
IVRT (ms) *	102.0 (81.0-105.0) <sup>A</sup>	95.0 (57.0-108.0) <sup>A</sup>	51.0 (38.0-60.5) <sup>B</sup>	0.0083
$E_{TDI}$ (cm/s)	12.5 (1.5) <sup>A</sup>	12.4 (0.9) <sup>A</sup>	8.5 (2.1) <sup>B</sup>	0.0002
$A_{TDI}$ (cm/s) *	7.6 (7.1-8.9) <sup>A</sup>	9.4 (7.2-9.6) <sup>AB</sup>	13.4 (11.6-15.9) <sup>B</sup>	0.0037

\* Nonparametric data (Medians and IQR are shown)

**Table 2** - Means (SD) or medians (IQR) of the calculated echocardiographic indices used to assess diastolic function in healthy (n=9) and MMVD dogs (n=12).


	Groups			P
	Healthy	Stage B2	Stage C	
$E_m/A_m$	1.5 (0.3) <sup>A</sup>	1.1 (0.3) <sup>B</sup>	1.2 (0.1) <sup>AB</sup>	0.0243
$E_{TDI}/A_{TDI}$	1.6 (0.2) <sup>A</sup>	1.4 (0.4) <sup>A</sup>	0.6 (0.1) <sup>B</sup>	<0.0001
$E_m/E_{TDI}$ *	5.8 (5.3-7.0)	6.7 (6.2-7.5)	10.1 (6.0-14.9)	0.0748
$A_m/A_{TDI}$	6.5 (2.3) <sup>AB</sup>	9.1 (3.2) <sup>B</sup>	5.1 (2.3) <sup>A</sup>	0.0470

\* Nonparametric data (Medians and IQR are shown)


**Table 3** - Means (SD) or medians (IQR) of the echocardiographic data used to assess either cardiac morphology or systolic function in healthy (n=9) and MMVD dogs (n=12).

	Groups			P
	Healthy	Stage B2	Stage C	
LA/Ao*	1.2 (1.1-1.2) <sup>A</sup>	1.7 (1.5-2.1) <sup>B</sup>	1.8 (1.6-3.0) <sup>B</sup>	0.0004
$LV_d$ (mm/m <sup>2</sup> )	49.3 (7.4) <sup>A</sup>	62.2 (11.4) <sup>AB</sup>	71.3 (18.4) <sup>B</sup>	0.0110
$LV_s$ (mm/m <sup>2</sup> )	36.3 (11.6)	39.3 (8.7)	41.0 (6.5)	0.6746
FS (%)	37.4 (5.6)	37.1 (9.5)	45.4 (6.4)	0.1251
EF (%)	68.9 (6.6)	67.1 (10.9)	77.6 (6.1)	0.1008
$S_{TDI}$ (cm/s)	13.7 (2.4)	14.4 (2.6)	14.9 (2.3)	0.6689

\* Nonparametric data (Medians and IQR are shown)



**Figure 1** - Scatterplots showing the mild-to-moderate correlations between the echocardiographic surrogates for cardiac structural remodeling ( $LA/Ao$ ,  $LV_d$ ) and the parameters used to assess diastolic function. Best-fit lines are shown.



**Figure 2** - Scatterplots showing the mild-to-moderate correlations between the echocardiographic surrogates for systolic function ( $FS$ ,  $EF$ ,  $S_{TDI}$ ) and the parameters used to assess diastolic function. Best-fit lines are shown.

## DISCUSSION

The echocardiogram was performed following the guidelines reported by Kienle and Thomas (2004) and Boon (2011), with the aim of obtaining images that were suitable for measurement of all parameters included in this investigation.

The changes documented in  $LV_d$  in MMVD as compared to the healthy dogs are related to the morphological change attributable to the activation of the renin-angiotensin-aldosterone system, therefore resulting in increased preload. The eccentric hypertrophy is a consequence of chronic volume overload, which becomes more evident with the progression of the valvular disease. A similar remodeling was previously reported by Pedersen (2000) and Mucha (2001), who studied dogs with MMVD and chronic congestive heart failure. In another study, Firm and Petric (2002) reported that the left ventricular end-diastolic diameter may be a prognostic surrogate concerning the progression of the cardiac disease.

The LA-to-Ao ratio was significantly different between MMVD and healthy dogs, reflecting the volume overload that accompanies the progression of MMVD, therefore resulting in increased left-ventricular filling pressure (Borghenagen, 1977). This condition is clearly responsible for the congestion heart failure and the consequent cardiac remodeling that follows the natural progression of MMVD in dogs.

Concerning systolic function, no differences were observed between the parameter obtained in MMVD and healthy dogs. However, in spite of the absence of difference in FS and EF between groups, a clear trend of increase was observed when stage C MMVD dogs were compared with the healthy controls. This finding is likely attributable to volume overload and the Frank-Starling principle (Kittleson, 2006; Boon, 2011), which plays an important role in MMVD once remodeling exists.

Even though the peak velocity of left ventricular rapid filling ( $E_m$ ) was not different between groups, a significant difference existed for  $A_m$  between healthy and stage B2 MMVD dogs, which points towards an increased preload and a major role played by the late ventricular filling in end-diastolic volume (KIENLE & THOMAS, 2004). This finding might indicate an increased left ventricular filling pressure and a consequent diastolic dysfunction, (BOON, 2011). Interestingly, no differences existed for  $A_m$  between healthy and stage C dogs, but this finding is likely related to the progression of diastolic dysfunction to pseudonormalization, which results in a normal  $E_m$ -to- $A_m$  ratio. All these findings possibly reflect the structural and hemodynamic modifications that develop with the intensification of congestive heart failure ascribed to MMVD (CAMACHO, 1996; MUCHA, 2001).

The tissue Doppler assessment showed a lower  $E_{TDI}$  and a higher  $A_{TDI}$  for MMVD stage C dogs as compared with both healthy and MMVD stage B2 dogs. The average  $E_{TDI}/A_{TDI}$  remained below 1 for the majority of stage C dogs, which contrasted with the healthy animals and pointed to diastolic dysfunction (OYAMA, 2004). This finding is probably ascribed to

the augmented left ventricular filling pressure, therefore resulting in a minor role played by the rapid component of ventricular filling and the intensification of congestion. Also, the inversed  $E_{TDI}$ -to- $A_{TDI}$  ratio is supportive of the cardiac remodeling reported by Bonagura (2009), who described an impaired relaxation in dogs with MMVD, as well as the deterioration of diastolic function with the progression of congestive heart failure. On the other hand, the systolic myocardial velocity ( $S_{TDI}$ ) attained no difference between healthy and diseased dogs, which is in agreement with the absence of an overt compromise in systolic function already shown by other echocardiographic indicators of contractility (Boon, 2011).

In our study, the intensification of MMVD was clearly associated with an elevation in the  $E_m$ -to- $E_{TDI}$  ratio, even though no significant differences between groups could be documented. This parameter was previously shown to be an useful surrogate for left ventricular filling pressure, therefore permitting the echocardiographic assessment of congestion. Omnem (2000) and Schober (2008) reported that changes in ventricular diastole are responsible for alterations in the  $E_m$ -to- $E_{TDI}$  ratio, which might be associated with a worse prognosis. In general, the average  $E_m/E_{TDI}$  increased with from 5.8 in healthy dogs to 6.7 and 10.1 in stages B2 and C MMVD dogs, showing that filling pressure and congestion was more intense in dogs with valve degeneration as compared with the normal subjects.

Even though this investigation found interesting results regarding diastolic dysfunction in dogs with MMVD, we do acknowledge its several limitations, which include the small number of animals enrolled, the absence of MMVD dogs in stages B1 and D, the absence of further assessment of diastolic function, including speckle tracking analysis, and, last but not least, the absence of follow-up assessment to evaluate the progression of MMVD and how the echocardiographic surrogate of diastolic function change over time.

## CONCLUSION

This study documented morphological remodeling associated with the progression of MMVD in dogs. Also, we identified several echocardiographic parameters that are supportive of diastolic impairment, especially in stage C dogs. Further studies are warranted to investigate how diastolic dysfunction interferes with survival times and the animal's tendency to evolve into overt congestive heart failure.

## REFERÊNCIAS

ANKER S. D.; NEGASSA, A.; COATS, A. J. et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. **Lancet**, v.361, p.1077-1083, 2003.

ANKER S. D.; STEINBORN, W.; STRASSBURG, S. Cardiac cachexia. **Ann Med**, v.36, n.7, p.518-529, 2004.

- ATKINS, C. E. et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. **JAVMA**, v.231, n.7, p.1061-1069, 2007.
- ATKINS, C. Enalapril monotherapy in asymptomatic mitral regurgitation: results of the VetProof trial. In: **Proceedings of the 20th ACVIM Forum**, p.75-76, 2002.
- BAKER, D.; ELLIOT, D. Nutritional management of early cardiac disease: ACT with SPEED. **Veterinary Focus**, v.18, n.3, p.32-35, 2008.
- BAHL, V. K.; MALHOTRA, O. P.; KUMAR, D. et al. Noninvasive assessment of systolic and diastolic left ventricular function in patients with chronic severe anemia: a combined M-mode, two-dimensional and Doppler echocardiographic study. **Am Heart J**, v.124, n.6, p.1516-1523, 1992.
- BEARDOW, A. W.; BUCHANAN, J. W. Chronic mitral valve leaflet: Report on fourteen patients. **Circulation**, v.38, p.763-770, 1968.
- BEARDOW, A. W.; BUCHANAN, J. W. Chronic mitral valvedisease in Cavalier King Charles Spaniels: 95 cases (1987-1991). **Journal JAVMA**, v.203, n.7, p.1023-1029, 1993.
- BITTAR, N.; SOSA, J. A. The billowing mitral valve leaflet: report on fourteen patients. **Circulation**, v.38, p.763-770, 1968.
- BILLER, B.; HORAUF, A.; KRAFT, W. Treatment of mitral valve insufficiency in dogs with the ACE inhibitor enalapril. A clinical progress study. **Medizinische Klinik (Praxis-Ausg)**, v.26, n.1, p.21-31, 1998.
- BILLMAN, G. E.; KANG, J. X.; LEAF, A. Prevention of sudden cardiac death by dietary pure n-3 polyunsaturated fatty acids. **Circulation**, v.99, p.2452-2457, 1999.
- BOON, J. A. **Manual of Veterinary Echocardiography**. 2.ed., Baltimore: Williams & Wilkins, 2011.
- BONAGURA, J. D.; MILLER, M. W.; DARKE, P. G. G. Doppler echocardiography I: pulsed-wave and continuous-wave examinations. **Vet Clin North Am Small Anim Pract**, Philadelphia, v.28, n6, p.1325-1359, 1998.
- BONAGURA, J. D., SCHOBER, K. E. Can ventricular function be assessed by echocardiography in chronic canine mitral valve disease. **J Small Anim Pract.**, v.50, p.12-24, 2009.
- BORGARELLI, M; ZINI, E.; D'AGNOLO, G. et al. Comparison of primary mitral valve disease in German Shepherd dogs and in small breeds. **J Vet Cardiol**, n.6, p.25-31, 2004.
- BORGENHAGEN, D. M.; SERUR, J. R.; GORLIN, R. et al. The effects of left ventricular load and contractility on mitral regurgitant orifice size and flow in the dog. **Circulation**, v.56, n.1, p.106-113, 1977.
- BOSWOOD, A. Biomarkers in cardiovascular disease: beyond natriuretic peptides, **J Vet Cardiol**, n.11, v.3, p.1-10, 2009.
- BRAUNWALD, E.; AWE, W.C. The syndrome severe mitralregurgitation with normal left atrial pressure. **Circulation**. v.27, p.21-35, 1963.
- BRAUNWALD, E. Mitral regurgitation. Physiologic, clinical and surgical considerations. **Seminars in Medicine of the Beth Israel Hospital Boston**. v.281, p.425-433, 1969.
- BRAUNWALD, E.; TURI, Z. G. Pathophysiology of mitral valve disease. In WELLS, F.C., SHAPIRO, L.M. **Mitral valve disease**. Oxford: Butterworth-Heinemann, 1996, cap. 5, p.28-36.
- BUCHANAN, J. W. Chronic valvular disease (endocardiosis) in dogs. **Adv Vet Sci**, v.21, p.75-106, 1977.
- BUCHANAN, J. W.; BÜCHELER, J. Vertebral scale system to measure canine heart size in radiographs. **JAVMA**, v.206, n.2, p.194-199, 1995.
- CAMACHO, A. A. Estudo clínico, caracterização morfológica e quantitativa dos neurônios ganglionares atriais da faixa intercaval de cães com miocardiopatia dilatada.congestiva idiopática.1996. 56f. Tese (livre Docência)- Faculdade de Ciências Agrárias e Veterinárias, Universidade Estadual Paulista, Jaboticabal, 1996.
- DARKE, P. G. G.; BONAGURA, J. D.; MILLER, M. Transducer orientation for Doppler echocardiography in dogs. **J Small Anim Pract**, v.34, p.2-8, 1993.
- ESTHER JR, C. R.; MARINO, E. M.; BERNSTEIN, K. E. The role of angiotensin-converting enzyme in blood pressure control, renal function and male fertility. **Trends in Endocr Metabol**, v.8, n.5, p.181-186,1997.
- FILIPPATOS, G. S.; KANATSELOS, C.; MANOLATOS, D. D.; et al. Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia. **Int J Cardiol**, v.90, n.1, p.107-113, 2003.
- FIRM, I., PETRIC, A. D. Epidemiological study o myxomatous valvular disease – A retrospective study of 195 cases. 2002. Disponível em [www.vin.com/proceedings/proceedings.plx/cid=WSAV](http://www.vin.com/proceedings/proceedings.plx/cid=WSAV) A 2002. Acesso em 23 de outubro de 2007.
- FREEMAN, L. M.; RUSH, J. E. Cardiovascular diseases: nutritional modulation. In: PIBOT, P.;

- BIOURGE, V.; ELLIOT, D. **Encyclopedia of Canine Clinical Nutrition**, Aniwa SAS, 2006, p.316-341.
- GABER, C. Doppler echocardiography. **Probl Vet Med**, v.3, n.4, p.500-519, 1991.
- HÄGGSTRÖM, J.; HANSSON, K.; KVART, C. et al. Chronic valvular disease in the Cavalier King Charles Spaniel in Sweden. **Vet Rec**, v.12, p.549-553, 1992.
- HÄGGSTRÖM, J.; KVART, C.; HANSON, K. Heart sounds and murmurs: changes related to severity of chronic valvular disease in the Cavalier King Charles Spaniel. **J Vet Intern Med**, v.9, n.2, p.75-85, 1995.
- HÄGGSTRÖM, J.; HANSSON, K.; KVART, C. et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. **Am J Vet Res**, v.58, n.1, p.77-82, 1997.
- HÄGGSTRÖM, J. Update on chronic valvular disease in dogs. **Abstracts of WSAVA/FECAVA World congress**, p.38-39, 2000.
- HAMLIN, R. L.; BENITZ, A. M.; ERICSSON, G. F. et al. Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. **J Vet Intern Med**, v.10, n.10, p.85-87, 1996.
- HELLWIG, C. A. Atheromatosis of the mitral valve. **Am Heart J**, v.57, p.41-49, 1942.
- HENIK, R.A. Echocardiography and doppler ultrasound. In: MILLER, M. S.; TILLEY, L. P. **Manual of canine and feline cardiology**. 2 ed. Philadelphia: W.B. Saunders, 1995, p.75-107.
- International Small Animal Cardiac Health Council (ISACHC). Recommendations for the diagnosis of heart disease and the treatment of heart failure in small animals. In: MILLER, M. S.; TILLEY, L. P. **Manual of canine and feline cardiology**. 2 ed. Philadelphia: W.B. Saunders, 1995, p.150.
- KEENE, B. W. Chronic valvular disease in the dog. In: FOX, P. R. **Canine and feline cardiology**. New York: Churchill Livingstone, 1988, p.409-419.
- KENNE, B. W.; RUSH, J. E. Terapia da insuficiência cardíaca. In: ETTINGER, S. J.; FELDMAN, E. **Tratado de medicina interna veterinária**. São Paulo: Manole, 1997, p. 1219-1253.
- KEENE, B. W. Dilated cardiomyopathy in dogs: diagnosis and long term management. In: **18<sup>th</sup> Waltham/OSU Symposium**, 1994, p.27-32.
- KERN, W. H.; TUCKER, B. L. Mixoid changes in cardiac valves: pathological, clinical and ultrastructural studies. **Am Heart J**, v.84, n.3, p.294-301, 1972.
- KIENLE, R. D.; THOMAS, W. P. Ecocardiografia. In: NYLAND, T. G.; MATTOON, J. S. **Ultra-som diagnóstico em pequenos animais**. 2 ed, São Paulo: Roca, 2004, p.368-438.
- KING, B. D.; CLARK, M. A.; MOBUSHIS, B. et al. Myxomatous mitral valves: collagen dissolution as the primary defect. **Circulation**, v.66, n.2, p.288-296, 1982.
- KITAGAWA, H.; WAKAMIYA, H.; KITOH, K. et al. Efficacy of monotherapy with benazepril, an angiotensin-converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. **J Vet Med Sci**, v.59, p.513-520, 1997.
- KITTLESON, M. D.; HAMLIN, R. L. Hydralazine therapy for severe mitral regurgitation in a dog. **J Vet Med Assoc**, v.179, n.9, p.903-905, 1981.
- KITTLESON, M. D. Myxomatous atrioventricular valvular degeneration. In: KITTLESON, M. D.; KIENLE, R. D. **Small animal cardiovascular medicine**. St Louis: Mosby, 1998, p.297-318.
- KNIGHT, D. H. Fisiopatologia da insuficiência cardíaca. In: ETTINGER, S. J.; FELDMAN, E. **Tratado de medicina interna veterinária**. São Paulo: Manole, 1992. p.944-969.
- KOGICA, M. M. Diuréticos. In: SPINOSA, M. M.; GÓRNIK, S. L.; BERNARDI, M. M. **Farmacologia aplicada à medicina veterinária**. 2 ed., Rio de Janeiro: Guanabara-Koogan, 1999, p.269-276.
- KVART, C.; HÄGGSTRÖM, J.; PEDERSEN, D. et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitations. **J Vet Intern Med**, v.16, p.60-88, 2002.
- KOCH, J.; PEDERSEN, H.; JENSEN A. et al. Short term effects of acute inhibition of the angiotensin-converting enzyme on the renin-angiotensin system and plasma atrial natriuretic peptide in healthy dogs fed a low-sodium diet versus a normal sodium diet. **J Vet Intern Med**, v.41, p.121-127, 1994.
- MOÏSE, N. S. Echocardiography. In: FOX, P. R. **Canine and feline cardiology**. New York: Churchill Livingstone, 1988, p.113-156.
- MOW, T.; PEDERSEN, H. D. Increased endothelin receptor density in myxomatous canine mitral valve leaflets. **J Cardiovasc Pharmacol**, n.34, p.254-260, 1999.
- MUCHA, C. J.; CAMACHO, A. A. Determinação da pressão arterial. In: BELERENIAN, G. C.; MUCHA, C. J.; CAMACHO, A.A. **Afeções cardiovasculares em pequenos animais**. São Caetano do Sul: Interbook, 2003, p.68-71.

- MUCHA, C. J. Insuficiencia valvular mitral: endocardiosis mitral. In: BELERENIAN, G. C.; MUCHA, C. J.; CAMACHO, A. A. Afecciones cardiovasculares en pequeños animales. Buenos Aires: Intermedica, 2001, p.155-152.
- PEDERSEN, H. D.; HÄGGSTRÖM J. Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. **Cardiovas Res**, v.47, p.234-243, 2000.
- PEDERSEN, H.; KOCH, J.; JENSEN, A. et al. Some effects of low sodium diet high in potassium on the renin-angiotensin system and plasma electrolyte concentrations in normal dogs. **Acta Vet Scand**, v.35, p.133-140, 1994.
- PEDERSEN, H. Effects of mild mitral valve insufficiency, sodium intake and place of blood sampling on the renin-angiotensin system in dogs. **Acta Vet Scand**, v.37, p.109-118, 1996.
- POEHLMAN, E. T.; SCHEFFERS, J.; GOTTLIEB, S. S. et al. Increased resting metabolic rate in patients with congestive heart failure. **Ann Intern Med**, v.21, p.860-862, 1994.
- POMERANCE, A. Pathogenesis of "senile" nodular sclerosis of atrio-ventricular valves. **Br Heart J**, v.28, p.815-823, 1966.
- POMERANCE, A. Ageing changes in human heart valves. **Br Heart J**, v.29, p.222-231, 1967.
- POMERANCE, A. Balloning deformity (mucoïd degeneration) of atrioventricular valves. **Br Heart J**, v.31, p.343-351, 1969.
- POMERANCE, A. Pathology and valvular heart disease. **Br Heart J**, v.34, p.437-443, 1972.
- POMERANCE, A.; WIHTNEY, J. C. Heart valve changes common to man and dog: a comparative study. **Cardiovasc Res**, v.4, p.61-66, 1970.
- RAO, P. V. **Statistical research methods in life sciences**. Pacific Groove: Duscbury Press, 1998, 889p.
- RUSH, J.; FREEMAN, L. Sistema cardiovascular. In: GOLDSTON, R.; HOSKINS, J. Geriatria y gerontologia del perro y del gato. Buenos Aires: Intermedica, 1997, cap. 5, p. 103-132.
- SHAH, P. V. Echocardiography in congestive or dilated cardiomyopathy. **J Am Soc Echocardiogr**, v.1, p.20-30, 1998.
- SOFFER, R. L. Angiotensin-converting enzyme and the regulation vasoactive peptides. **Ann Rev Bioch.** v.45. p.73-94, 1976.
- SONNENBLICK, E. H.; DAGGET, W. M.; COOPER, T. Active contraction of the mitral valve: intrinsic neuromuscular basis for valvular motion. **Circulation**, v.34 (supl.III), p. III-221, 1966.
- TILLEY, L. P. Interpretations of Q, R, S, T deflections. In: TILLEY, L. P. **Essentials of canine and feline electrocardiography**. 3 ed., Philadelphia: Lea & Febiger, 1992, p.59-99.
- VAN TASSE, B. W.; ARENA, R. A.; TOLDO, S.; MEZZAROMA, E.; AZAM, T. et al. (2012) Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure. **PLoS ONE** 7(3): e33438. doi:10.1371/journal.pone.0033438
- VIRMANI, R.; ATKINSON, J. B.; BYRD, B. F. et al. Abnormal chordal insertion: a cause of mitral valve prolapse. **Am Heart J**, v.113, n.4, p.851-858, 1987.
- WARE, W. A. Enfermedades valvulares y endocárdicas adquiridas. In NELSON, R. W.; COUTO, C. G. Medicina interna de animales pequeños. 2 ed., Buenos Aires: Intermedica, cap. 8, p.144-157, 2000.
- WHITNEY, J. C. Observations on the effect of age on the severity of heart valve lesions in the dog. **J Small Anim Pract.** v.15, p.511, 1974.